ScholarIQanswers from OpenAlex & ORCID
Proton Rahman
ResearcherPublications, citations & collaboration network
Proton Rahman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Proton Rahman have?
ScholarIQindexed works
Proton Rahman has 513 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Proton Rahman have?
ScholarIQcitation count
Proton Rahman has 25,170 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Proton Rahman?
ScholarIQh-index
Proton Rahman has an h-index of 77 in OpenAlex.
What is the i10-index of Proton Rahman?
ScholarIQi10-index
Proton Rahman has an i10-index of 234 in OpenAlex.
What is the ORCID of Proton Rahman?
ScholarIQorcid
The ORCID for Proton Rahman is on the source record.
What is the OpenAlex record for Proton Rahman?
ScholarIQopenalex
The OpenAlex for Proton Rahman is on the source record.
What are the most-cited papers on Proton Rahman?
ScholarIQmost cited works
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
Rajan P. Nair, Kristina Callis Duffin, Cynthia Helms, Jun Ding, Philip E. Stuart, David E. Goldgar, Jóhann E. Guðjónsson, Yun Li, Trilokraj Tejasvi, Bing Feng, Andreas Ruether, Stefan Schreiber, Michael Weichenthal, Dafna D. Gladman, Proton Rahman, Steven J. Schrodi, Sampath Prahalad, Stephen L. Guthery, Judith Fischer, Wilson Liao, Pui–Yan Kwok, Alan Menter, G.M. Lathrop, Carol A. Wise, Ann B. Begovich, John J. Voorhees, Elder Jt, Gerald G. Krueger, A. Bowcock, Gonçalo R. Abecasis
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Lam C. Tsoi, Sarah L. Spain, Jo Knight, Eva Ellinghaus, Philip E. Stuart, Francesca Capon, Jun Ding, Yanming Li, Trilokraj Tejasvi, Jóhann E. Guðjónsson, Hyun Min Kang, Michael H. Allen, Ross McManus, Giuseppe Novelli, Lena Samuelsson, Joost Schalkwijk, Mona Ståhle, A. David Burden, Catherine Smith, Michael J. Cork, Xavier Estivill, A. Bowcock, Gerald G. Krueger, Wolfgang Weger, Jane Worthington, Rachid Tazi‐Ahnini, Frank O. Nestlé, Adrian Hayday, Per Hoffmann, Juliane Winkelmann, Cisca Wijmenga, Cordelia Langford, Sarah Edkins, Robert Andrews, Hannah Blackburn, Amy Strange, Gavin Band, Richard D. Pearson, Damjan Vukcevic, Chris C. A. Spencer, Panos Deloukas, Ulrich Mrowietz, Stefan Schreiber, Stephan Weidinger, Sulev Kõks, Külli Kingo, Tõnu Esko, Andres Metspalu, Henry W. Lim, John J. Voorhees, Michael Weichenthal, H.‐Erich Wichmann, Vinod Chandran, Cheryl F. Rosen, Proton Rahman, Dafna D. Gladman, C.E.M. Griffiths, André Reis, Juha Kere, Rajan P. Nair, André Franke, Jonathan N W N Barker, Gonçalo R. Abecasis, James T Elder, Richard C. Trembath
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip J. Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, Kenneth Abrams